原发性和转移性胸膜based肿瘤经皮冷冻消融的安全性和有效性
回顾性研究评估经皮冷冻消融治疗胸膜based胸部恶性肿瘤的安全性和局部肿瘤无进展生存期(LTPFS),共46例患者、62个病灶、59次消融。技术成功率98.3%,中位LTPFS为14.4个月,肿瘤大小是LTPFS的显著预测因子(HR 1.21),并发症发生率47.5%,多数轻微且自限。
要点
- 胸膜based肿瘤冷冻消融技术成功率高(98.3%),中位局部肿瘤无进展生存期14.4个月。
- 肿瘤大小是局部肿瘤无进展生存期的显著预测因子(HR 1.21,95%CI 1.03-1.44,p=0.023)。
- 并发症常见(47.5%),但严重并发症(≥D级)仅3.4%,疼痛和气胸最常见。
核心结论
- 经皮冷冻消融治疗胸膜病灶可获得较长的局部控制时间,大多数并发症轻微且自限。
研究设计与样本
- 回顾性研究,纳入46例患者(17例姑息治疗、9例寡进展、20例根治性意图),共62个胸膜based胸部病灶,进行59次冷冻消融,治疗时间为2005年9月至2021年11月,使用CryoCare CS(Varian, Irvine, CA)或IceFORCE(Boston Scientific, Marlborough, MA)系统;对根治性意图和/或寡进展肿瘤采用Kaplan-Meier法估计LTPFS和总生存期(OS),术后并发症报告所有 sessions(包括姑息意图),单因素分析计算并发症风险增加的相关因素。
诊断标准与关键数值
- 技术成功率为98.3%(59次治疗中);中位LTPFS为14.4个月(95%CI 9.4-25.6);肿瘤大小是LTPFS的显著预测因子(HR 1.21,95%CI 1.03-1.44,p=0.023);中位OS为52.4个月(95%CI 28.1-未达到);并发症发生率为47.5%(28/59次),≥D级(介入放射学会不良事件标准)为3.4%(2/59次,死亡;出院时需补充氧气的低氧血症);疼痛和气胸是最常见并发症;肺实质穿越长度是气胸的显著预测因子(HR 0.48,95%CI 0.14-0.83,p=0.0024)。
临床应用与阅片要点
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: Assess safety and local tumor progression-free survival (LTPFS) of percutaneous cryoablation for pleural-based thoracic malignancies.
MATERIALS AND METHODS: Retrospective study of 46 patients (17 treated for palliation; 9 for oligoprogression; 20 for curative intent), with 62 pleural-based thoracic lesions, treated in 59 cryoablation sessions. Patients were treated from 9/2005-11/2021 with CryoCare CS (Varian, Irvine, CA) or IceFORCE (Boston Scientific, Marlborough, MA) systems. For tumors treated with curative intent and/or oligoprogression, LTPFS of the treated tumor(s) and overall survival (OS) were estimated using Kaplan-Meier method. Post-operative complications were reported for all sessions, including those with palliative intent; univariate analyses were used to calculate factors associated with increased complication risk.
RESULTS: Median number of tumors treated in a single treatment session was 1 (range 1-4). Largest dimension of the treated tumor was 2.1 cm [IQR:0.9-5 cm]. Of the 59 treatments, 98.3 % were technically successful. Median LTPFS was 14.4 (95 % CI: 9.4-25.6) months. Tumor size was a significant predictor of LTPFS (HR: 1.21, 95 % CI: 1.03-1.44, p = 0.023). Median OS was 52.4 (28.1-NR) months. Complications occurred in 28/59 sessions (47.5 %); 2/59 (3.4 %) were ≥ grade D by Society of Interventional Radiology adverse event criteria (death; hypoxia requiring supplemental oxygen upon discharge). Pain and pneumothorax were the most common complications. The length of lung parenchyma traversed was a significant predictor of pneumothorax: HR 0.48 (95 %CI: 0.14-0.83), p = 0.0024.
CONCLUSION: Percutaneous cryoablation for pleural lesions is associated with a long duration of local control and most complications were minor and self-limited.
引用
- Alexander ES, Petre EN, Offin M, et al. Safety and efficacy of percutaneous cryoablation for primary and metastatic pleural based tumors. Eur J Radiol. 2024. PMID: 38621339. doi:10.1016/j.ejrad.2024.111465
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。